Oxford Finance LLC

Type

Other

Status

Active

Location

Alexandria, United States

Total investments

151

Average round size

36M

Portfolio companies

136

Rounds per year

6.86

Lead investments

36

Follow on index

0.09

Exits

79

Stages of investment
Early Stage VentureLate Stage Venture
Areas of investment
BiotechnologyHealth CareHealth DiagnosticsGeneticsMedical DeviceMedicalLife SciencePharmaceuticalTherapeuticsBiopharma

Summary

In 2002 was created Oxford Finance LLC, which is appeared as Corporate Investor. The fund was located in North America if to be more exact in United States. The main department of described Corporate Investor is located in the Alexandria.

Besides, a startup needs to be aged 11-15 years to get the investment from the fund. Among the most popular fund investment industries, there are Medical, Biopharma. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. The fund has exact preference in a number of founders of portfolio startups. In case when startup counts 4 or 5+ of the founder, the chance for it to get the investment is meager. Among the most popular portfolio startups of the fund, we may highlight Avanir Pharmaceuticals, Auspex Pharmaceuticals, Ignyta.

The typical case for the fund is to invest in rounds with 1-2 participants. Despite the Oxford Finance LLC, startups are often financed by Versant Ventures, Silicon Valley Bank, Venrock. The meaningful sponsors for the fund in investment in the same round are MidCap Financial, Silicon Valley Bank, Square 1 Bank. In the next rounds fund is usually obtained by Vivo Capital, Versant Ventures, Accuitive Medical Ventures.

The fund is constantly included in 7-12 deals per year. The top activity for fund was in 2014. Despite it in 2019 the fund had an activity. The top amount of exits for fund were in 2014. Considering the real fund results, this Corporate Investor is 6 percentage points more often commits exit comparing to other organizations. Comparing to the other companies, this Oxford Finance LLC performs on 22 percentage points more the average number of lead investments. Deals in the range of 10 - 50 millions dollars are the general things for fund.

Show more

Investor highlights

Discover reliable insights

Find relevant VC investors, identify key contacts and secure funding opportunities.

Investments analytics

Analytics

Total investments
151
Lead investments
36
Exits
79
Rounds per year
6.86
Follow on index
0.09
Investments by industry
  • Health Care (104)
  • Biotechnology (101)
  • Medical (51)
  • Medical Device (46)
  • Pharmaceutical (39)
  • Show 57 more
Investments by region
  • United States (134)
  • United Kingdom (6)
  • Canada (3)
  • Switzerland (1)
  • Ireland (1)
  • Show 1 more
Peak activity year
2014
Number of Unicorns
6
Number of Decacorns
6
Number of Minotaurs
4

Discover reliable insights

Leverage validated data, identify key contacts and secure funding opportunities for your business.

Quantitative data

Avg. startup age at the time of investment
17
Avg. valuation at time of investment
89M
Group Appearance index
0.48
Avg. company exit year
10
Avg. multiplicator
1.52
Strategy success index
1.00

Need more data?

Get access to full data about investors, including their team, contact information, and historic data.

Latest deals

Company name Deal date Industry Deal stage Deal size Location
Platelet BioGenesis 04 Nov 2021 Biotechnology, Life Science, Ediscovery Early Stage Venture 75M United States, Massachusetts, Newton

Similar funds

By same location

By same geo focus

By doing lead investments

How we get our data

At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).

Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.